Stem cell developers shift focus to FDA hearings

Everyone involved in embryonic stem cell programs will be paying close attention to hearings the FDA is holding on how they plan to regulate the field. Developers want a much clearer idea of the regulatory pathway they'll have to follow to gain approvals. And they're looking for some assurances that the agency won't adopt the political leanings of the Bush administration--a longtime opponent of ESC research--when it comes to making critical decisions. It's a tough position to be in, notes Richard Garr, CEO of Neuralstem, which is advancing adult stem cell therapies. Garr's "nightmare" scenario: Unresolved safety issues surrounding stem cells could cause the agency to apply the brakes on considering new therapies.

- read the story in The Wall Street Journal

ALSO: In new work that has both political as well as scientific implications, a team of scientists has been able to reprogram skin cells into functioning neurons and used them to eliminate symptoms of Parkinson's disease. Report

Related Articles:
Stem cell outfits a winner in upcoming election
NIH chief breaks with Bush on stem cell research
Stem cell advance runs into conservative roadblock
Stem cell market shows signs of fast growth

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.